Message Font: Serif | Sans-Serif
 
No. of Recommendations: 1
Although it will probably take another 2 years before this decision is finalized, the Patent Office overturned the Cabilly II patent.

Since this and its predecessor (Cabilly I) force any company that is producing Monoclonal antibodies to pay Genetech a royalty, I figured this would have a bigger impact on them. Are they still in the Avastin afterglow?

Do you think more companies will persue MaBs as a result of this decision?

Thanks,
Bruiser
Print the post  

Announcements

When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.
Advertisement